Austedo

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) investors got a pleasant surprise when the FDA approved the company’s Ingrezza drug for treatment of tardive dyskinesia (TD). While the approval itself was expected, Baird analyst Brian Skorney says the FDA’s generous labeling puts the drug at...